Anika Therapeutics' loss under GAAP for 6 months of 2020 amounted to $1,915 mln, compared to $13,942 mln in the previous year. Revenue increased by 19.8% to $66,075 million compared to $55,141 million a year earlier.
Anika Therapeutics' loss under GAAP for 6 months of 2020 amounted to $1,915 mln, compared to $13,942 mln in the previous year. Revenue increased by 19.8% to $66,075 million compared to $55,141 million a year earlier. 
ir.anikatherapeutics.com
English (US) 